Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025)

Nu-Med Plus (NUMD) posted Cash from Financing Activities of $33767.0 for Q4 2025, up 12.56% sequentially from $30000.0 in Q1 2021.

Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025) Analysis & Trends

Nu-Med Plus has reported Cash from Financing Activities for 11 years, with the latest figure at $33767.0 in Q4 2025.

Quarterly Cash from Financing Activities changed N/A year-over-year to $33767.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33767.0 (changed N/A YoY) and the FY2025 annual result came in at $46267.0, changed N/A from the prior year.
Cash from Financing Activities improved to $33767.0 in Q4 2025 per NUMD's latest filing, from $30000.0 in the prior quarter.
Over five years, Cash from Financing Activities peaked at $33767.0 in Q4 2025 and troughed at $30000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Abbott Laboratories	199.52 Bn	193.92 Bn	7.27 Bn	-3.52 Bn
2	Stryker	129.55 Bn	126.07 Bn	4.50 Bn	-95.00 Mn
3	Medtronic	119.60 Bn	110.38 Bn	6.41 Bn	-888.00 Mn
4	Boston Scientific	73.64 Bn	73.10 Bn	3.85 Bn	-410.00 Mn
5	Edwards Lifesciences	52.33 Bn	48.08 Bn	1.35 Bn	-300,000.00
6	Dexcom	34.69 Bn	32.74 Bn	830.00 Mn	-607.30 Mn
7	GE HealthCare Technologies	34.10 Bn	31.99 Bn	2.18 Bn	-236.00 Mn
8	Koninklijke Philips	26.43 Bn	23.11 Bn	4.55 Bn	-1.34 Bn
9	Steris	23.23 Bn	22.75 Bn	684.20 Mn	-213.50 Mn
10	Nu-Med Plus	2.03 Mn	2.02 Mn	-	-

Download Data